ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
EC Grants Orphan Designation to Sparsentan for IgA Nephropathy americanpharmaceuticalreview
February 24, 2021?Travere Therapeutics announced the European Commission (EC) has granted orphan designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD). -
Travere Announces Orphan Drug Designation for IgA Nephropathy Treatment americanpharmaceuticalreview
January 20, 2021Travere Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).
Pharma Sources Insight July 2025
